The C609T variant of NQO1 is associated with carotid artery plaques in patients with type 2 diabetes

Molecular Genetics and Metabolism

Volumn 97, Issue 1, 2009, Pages 85-90

  Han, Seung Jin ^a,b   Kang, Eun Seok ^c   Kim, Hyeong Jin ^d   Kim, So Hun ^e   Chun, Sung Wan ^c   Ahn, Chul Woo ^c   Cha, Bong Soo ^c   Nam, Moonsuk ^e   Lee, Hyun Chul ^b,c  

^a Ajou University School of Medicine   (South Korea)

^b Yonsei University   (South Korea)

^c Yonsei University College of Medicine   (South Korea)

^d Kwandong University College of Medicine   (South Korea)

^e Inha University School of Medicine   (South Korea)

Author keywords

Carotid artery plaque; Carotid atherosclerosis; NQO1; SNP; Type 2 diabetes

Indexed keywords

HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE QUINONE OXIDOREDUCTASE 1; OXIDOREDUCTASE; UNCLASSIFIED DRUG;

ADULT; ALLELE; ARTERIAL WALL THICKNESS; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BODY MASS; CAROTID ARTERY DISEASE; CAROTID ATHEROSCLEROSIS; CIGARETTE SMOKING; CONTROLLED STUDY; DISEASE DURATION; DNA POLYMORPHISM; ECHOGRAPHY; FEMALE; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SYSTOLIC BLOOD PRESSURE;

CAROTID ARTERY, COMMON; CAROTID STENOSIS; DIABETES MELLITUS, TYPE 2; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MIDDLE AGED; NAD(P)H DEHYDROGENASE (QUINONE); POLYMORPHISM, SINGLE NUCLEOTIDE; TUNICA INTIMA; TUNICA MEDIA;

EID: 63649102507     PISSN: 10967192     EISSN: 10967206     Source Type: Journal    
DOI: 10.1016/j.ymgme.2009.01.012     Document Type: Article

References (30)

1. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 54 (2005) 1615-1625
2. Ross D., Kepa J.K., Winski S.L., Beall H.D., Anwar A., and Siegel D. NAD(P)H:quinone oxidoreductase 1 (NQO1): chemoprotection, bioactivation, gene regulation and genetic polymorphisms. Chem. Biol. Interact. 129 (2000) 77-97
3. Riley R.J., and Workman P. DT-diaphorase and cancer chemotherapy. Biochem. Pharmacol. 43 (1992) 1657-1669
4. Zhu H., Jia Z., Mahaney J.E., Ross D., Misra H.P., Trush M.A., and Li Y. The highly expressed and inducible endogenous NAD(P)H:quinone oxidoreductase 1 in cardiovascular cells acts as a potential superoxide scavenger. Cardiovasc. Toxicol. 7 (2007) 202-211
5. Siegel D., Gustafson D.L., Dehn D.L., Han J.Y., Boonchoong P., Berliner L.J., and Ross D. NAD(P)H:quinone oxidoreductase 1: role as a superoxide scavenger. Mol. Pharmacol. 65 (2004) 1238-1247
6. Cooke J.P. Flow, NO, and atherogenesis. Proc. Natl. Acad. Sci. USA 100 (2003) 768-770
7. Chen X.L., Varner S.E., Rao A.S., Grey J.Y., Thomas S., Cook C.K., Wasserman M.A., Medford R.M., Jaiswal A.K., and Kunsch C. Laminar flow induction of antioxidant response element-mediated genes in endothelial cells. A novel anti-inflammatory mechanism. J. Biol. Chem. 278 (2003) 703-711
8. Siegel D., McGuinness S.M., Winski S.L., and Ross D. Genotype-phenotype relationships in studies of a polymorphism in NAD(P)H:quinone oxidoreductase 1. Pharmacogenetics 9 (1999) 113-121
9. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus, Diabetes Care 20 (1997) 1183-1197.
10. Kang E.S., Kim H.J., Ahn C.W., Park C.W., Cha B.S., Lim S.K., Kim K.R., and Lee H.C. Relationship of serum high sensitivity C-reactive protein to metabolic syndrome and microvascular complications in type 2 diabetes. Diabetes Res. Clin. Pract. 69 (2005) 151-159
11. North K.E., MacCluer J.W., Devereux R.B., Howard B.V., Welty T.K., Best L.G., Lee E.T., Fabsitz R.R., and Roman M.J. Heritability of carotid artery structure and function: the Strong Heart Family Study. Arterioscler. Thromb. Vasc. Biol. 22 (2002) 1698-1703
12. Kim S.H., Lee S.J., Kang E.S., Kang S., Hur K.Y., Lee H.J., Ahn C.W., Cha B.S., Yoo J.S., and Lee H.C. Effects of lifestyle modification on metabolic parameters and carotid intima-media thickness in patients with type 2 diabetes mellitus. Metabolism 55 (2006) 1053-1059
13. Yokoyama H., Aoki T., Imahori M., and Kuramitsu M. Subclinical atherosclerosis is increased in type 2 diabetic patients with microalbuminuria evaluated by intima-media thickness and pulse wave velocity. Kidney Int. 66 (2004) 448-454
14. Nioi P., and Hayes J.D. Contribution of NAD(P)H:quinone oxidoreductase 1 to protection against carcinogenesis, and regulation of its gene by the Nrf2 basic-region leucine zipper and the arylhydrocarbon receptor basic helix-loop-helix transcription factors. Mutat. Res. 555 (2004) 149-171
15. Chen X.L., Dodd G., Thomas S., Zhang X., Wasserman M.A., Rovin B.H., and Kunsch C. Activation of Nrf2/ARE pathway protects endothelial cells from oxidant injury and inhibits inflammatory gene expression. Am. J. Physiol. Heart. Circ. Physiol. 290 (2006) H1862-H1870
16. Pan S.S., Forrest G.L., Akman S.A., and Hu L.T. NAD(P)H:quinone oxidoreductase expression and mitomycin C resistance developed by human colon cancer HCT 116 cells. Cancer Res. 55 (1995) 330-335
17. Gaedigk A., Tyndale R.F., Jurima-Romet M., Sellers E.M., Grant D.M., and Leeder J.S. NAD(P)H:quinone oxidoreductase: polymorphisms and allele frequencies in Caucasian, Chinese and Canadian Native Indian and Inuit populations. Pharmacogenetics 8 (1998) 305-313
18. Isbir C.S., Ergen A., Tekeli A., Zeybek U., Gormus U., and Arsan S. The effect of NQO1 polymorphism on the inflammatory response in cardiopulmonary bypass. Cell Biochem. Funct. 26 (2007) 534-538
19. Willeit J., Kiechl S., Oberhollenzer F., Rungger G., Egger G., Bonora E., Mitterer M., and Muggeo M. Distinct risk profiles of early and advanced atherosclerosis: prospective results from the Bruneck Study. Arterioscler. Thromb. Vasc. Biol. 20 (2000) 529-537
20. Spence J.D., and Hegele R.A. Noninvasive phenotypes of atherosclerosis: similar windows but different views. Stroke 35 (2004) 649-653
21. Spence J.D. Measurement of intima-media thickness vs. carotid plaque: uses in patient care, genetic research and evaluation of new therapies. Int. J. Stroke 1 (2006) 216-221
22. Tabara Y., Kohara K., Nakura J., and Miki T. Risk factor-gene interaction in carotid atherosclerosis: effect of gene polymorphisms of renin-angiotensin system. J. Hum. Genet. 46 (2001) 278-284
23. Chapman C.M., Palmer L.J., McQuillan B.M., Hung J., Burley J., Hunt C., Thompson P.L., and Beilby J.P. Polymorphisms in the angiotensinogen gene are associated with carotid intimal-medial thickening in females from a community-based population. Atherosclerosis 159 (2001) 209-217
24. Hegele R.A. The pathogenesis of atherosclerosis. Clin. Chim. Acta 246 (1996) 21-38
25. Hegele R.A., Al-Shali K.Z., House A.A., Hanley A.J., Harris S.B., Mamakeesick M., Fenster A., Zinman B., Cao H., and Spence J.D. Disparate associations of a functional promoter polymorphism in PCK1 with carotid wall ultrasound traits. Stroke 36 (2005) 2566-2570
26. Al-Shali K.Z., House A.A., Hanley A.J., Khan H.M., Harris S.B., Zinman B., Mamakeesick M., Fenster A., Spence J.D., and Hegele R.A. Genetic variation in PPARG encoding peroxisome proliferator-activated receptor gamma associated with carotid atherosclerosis. Stroke 35 (2004) 2036-2040
27. Kim S.H., Kang E.S., Hur K.Y., Lee H.J., Han S.J., Kwak J.Y., Nam C.M., Ahn C.W., Cha B.S., and Lee H.C. Adiponectin gene polymorphism 45T>G is associated with carotid artery plaques in patients with type 2 diabetes mellitus. Metabolism 57 (2008) 274-279
28. Palming J., Sjoholm K., Jernas M., Lystig T.C., Gummesson A., Romeo S., Lonn L., Lonn M., Carlsson B., and Carlsson L.M. The expression of NAD(P)H:quinone oxidoreductase 1 is high in human adipose tissue, reduced by weight loss, and correlates with adiposity, insulin sensitivity, and markers of liver dysfunction. J. Clin. Endocrinol. Metab. 92 (2007) 2346-2352
29. Kelsey K.T., Ross D., Traver R.D., Christiani D.C., Zuo Z.F., Spitz M.R., Wang M., Xu X., Lee B.K., Schwartz B.S., and Wiencke J.K. Ethnic variation in the prevalence of a common NAD(P)H quinone oxidoreductase polymorphism and its implications for anti-cancer chemotherapy. Br. J. Cancer 76 (1997) 852-854
30. Kristiansen O.P., Larsen Z.M., Johannesen J., Nerup J., Mandrup-Poulsen T., and Pociot F. No linkage of P187S polymorphism in NAD(P)H: quinone oxidoreductase (NQO1/DIA4) and type 1 diabetes in the Danish population. DIEGG and DSGD. Danish IDDM Epidemiology and Genetics Group and The Danish Study Group of Diabetes in Childhood. Hum. Mutat. 14 (1999) 67-70